Trial
NCT02895945
BAX 802 in CHA With Inhibitors
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Baxalta now part of Shire
Collaborators
Baxalta Innovations GmbH, now part of Shire
Condition
Hemophilia A
Intervention
Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)
Why stopped
Takeda has determined that the benefit/risk profile does not support continuation of the surgery Study for this specific Congenital Hemophilia A with Inhibitors patient population.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-20